Commercial upscale of Recombinant Production

Octapharma’s Commercial Upscale R&D and Production unit manages the commercial development of recombinant products, from pilot study phases to a commercial scale.

 

Activities since 2006 have focused on bringing Octapharma’s first recombinant product, the B-domain-deleted human cell line recombinant Factor VIII (hcl-rFVIII), to the market. After successfully up-scaling to pilot plant and producing recombinant Factor VIII for toxicology studies, the group is now producing hcl-rFVIII for soon-to-finished phase III clinical studies and up-scaling to commercial production.

 

Preclinical production of further recombinant human proteins is also in development.

 

The unit is integrated within the Biotechnology Group of Octapharma AB in Stockholm.